About: fang

HONG KONG, August 1, 2025 - (ACN Newswire via SeaPRwire.com) - Recently, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, successfully issued its first digitally native bond. This bond, the first digital bond via public offering issued by a Chinese securities firm, was structured as a direct issue, denominated in U.S. dollars, with an amount of no more than US$300 million and a maturity of 3 years. GTJAI acted as left lead joint global coordinator and B&D bank for this issuance, using HSBC Orion1 as the digital assets platform.Digital bonds are bonds issued using blockchain or decentralized ledger technology (DLT). Their core features are digitization, programmability, and automated execution, which provide greater transparency, reducing costs and risks of settlement failures. In recent years, GTJAI has been making breakthroughs in the field of financial innovation and has actively led the innovative development of digital finance and digital asset business, of which the issue of digital bonds is one of the important initiatives in its deployment of blockchain technology and digitalized finance. In the first half of 2025, the Company submitted its digital bond business plan and received confirmation from the Hong Kong Securities and Futures Commission that it had no further questions on the plan and formally commenced its digital bond issue business.Mr. Zhang Xueming, Chief Financial Officer of GTJAI, said, “Successfully issuing the first publicly offered digital bond of a Chinese brokerage firm is a testament to our unwavering commitment to financial innovation and a showcase of our professional capabilities in digital finance and contribution to promoting digital assets. This transaction not only enhances operational efficiency and transparency for our clients and investors but also solidifies GTJAI’s leadership in pioneering next-generation capital market solutions.”Mr. John O’Neill, Group Head of Digital Assets & Currencies at HSBC, said, “We are pleased to support GTJAI in the first digital bond issuance by a Chinese brokerage firm in Hong Kong. This transaction demonstrates the capabilities of HSBC Orion to enable both a broader range of digital bonds and issuers. At HSBC, we are committed to building liquidity in digital fixed income, and see more corporates and financial institutions recognising the benefits of digital assets."The Company will also take this issue as an opportunity to further explore innovative directions such as cross-border digital asset circulation and the digitization of green finance, with a view to providing more digital solutions to the global financial market and contributing to the intelligent transformation and sustainable development of the international financial system.Notes:(1)HSBC Orion refers to the distributed ledger technology (DLT) platform deployed by HSBC to Central Moneymarkets Unit (CMU) as the DLT Platform Operator for the purposes of, among other things, creating and settling the DN Notes.About GTJAIGuotai Junan International (“GTJAI”, Stock Code: 1788.HK), a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH; 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 31, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK) has reaffirmed its confidence in long-term fundamentals by executing aggressive share buybacks on July 29 and 30, acquiring a total of 20.65 million shares at a cost of HK$37.93 million, with prices ranging from HK$1.80 to HK$1.87 per share.This is part of a broader buyback strategy—since early July, the company has repurchased over 36 million shares, totaling more than HK$66 million in capital deployed. According to management, these buybacks reflect not only near-term valuation confidence, but also long-term belief in the company’s strategic directions in robotics and healthcare technology."The buyback is not just about stabilizing the share price. It is an expression of long-term commitment to our shareholders and a vote of confidence in the commercial potential of our robotics and healthcare portfolios," the management stated.Portfolio Companies Advance Toward IPO MilestonesShoucheng’s capital return strategy is complemented by strong progress across its portfolio. Two of its most high-profile investees—IMUNOPHARM and Unitree Robotics—are now officially preparing for IPOs, signaling a near-term value realization window.IMUNOPHARM, a pioneer in China's CAR-T therapy space, signed a listing guidance agreement with CITIC Securities on July 23, 2025, officially launching its STAR Market IPO process. Meanwhile, Unitree Robotics signed its IPO guidance agreement earlier in July. Founded in 2016, Unitree is globally recognized for its leadership in quadruped and humanoid robotics, having pioneered the mass commercialization of high-performance legged robots. Its humanoid robots, the H1 and G1, are already in the market and featured at major global events including CES and the CCTV Spring Festival Gala. Unitree has filed over 200 patent applications and maintained profitability since 2020, with annual revenue exceeding RMB 1 billion.The dual IPO progression of IMUNOPHARM and Unitree not only validates Shoucheng’s early-stage investment judgment, but also signals that several of its frontier-tech bets are approaching monetization.Northeast Securities: Robotics Strategy Backed by Cash Flow, Industrial ScenariosAccording to Northeast Securities, Shoucheng Holdings is the leading operator of parking infrastructure in China, having repeatedly secured high-frequency contracts for major airport parking concessions, each with annual throughput in the tens of millions. The firm’s recurring and robust cash flow from its parking and industrial real estate operations provides the financial backbone for its strategic expansion into robotics investment.As China’s robotics industry enters a critical commercialization window, Shoucheng’s unique dual-engine model—“invest with the left hand, operate with the right”—has become its second growth curve.In early 2024, Shoucheng and Beijing Guoguan jointly launched the Beijing Robotics Industry Development Investment Fund, with an initial target size of RMB 10 billion. Since then, the firm has invested—through multiple fund platforms—in top-tier robotics companies such as Unitree Robotics, DEEP Robotics, Galbot, Volant Aerotech. These companies span humanoid robots, medical robots, industrial automation, and more.What makes Shoucheng’s robotics investment strategy distinctive is its built-in industrial scenario advantage. The company operates over 100 parking facilities and manages over 1 million square meters of industrial park space across China, offering abundant real-world testing environments. This accelerates product commercialization, feeds operational data back into product iterations, and enables co-evolution between Shoucheng and its portfolio companies.In February 2025, Shoucheng formally established Beijing Shoucheng Robotics Technology Co., Ltd., further institutionalizing its industrial platform. Going forward, the conversion of in-house scenarios into actual robotics purchase orders—including deployments via REIT-backed properties and industry-specific use cases—will continue to validate this integrated approach. With its platform now connecting capital, use-case, and demand, Shoucheng is expected to sustain strong visibility in robotics commercialization going forward.As both Imunopharm and Unitree Robotics—Shoucheng Holdings’ key portfolio companies in the fields of medical and robotics technologies—progress toward IPO, the company is approaching a critical inflection point where strategic investment begins to convert into tangible capital returns.The recent share buybacks are not only a direct signal of confidence in Shoucheng’s intrinsic value, but also reflect its precise grasp of the timing for value realization.Against the backdrop of a polarized valuation landscape in Hong Kong’s equity market, Shoucheng Holdings’ continuous buyback initiative helps stabilize investor sentiment while reinforcing market expectations. With the upcoming World Robot Conference and Humanoid Robot Games set to shine a spotlight on the sector, the company is poised to benefit from a convergence of commercialization momentum and valuation recovery.From infrastructure operator to technology value enabler, from strategic organizer to capital return executor—Shoucheng Holdings’ second growth curve is now visibly unfolding.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 30, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) welcomes the release of the "Report on Hong Kong’s Business Environment: Unique Strengths under 'One Country, Two Systems'" by the Hong Kong Special Administrative Region (HKSAR) today.Prof Frederick Ma, Chairman of the HKTDC, said, "This report details Hong Kong's business environment and advantages in various sectors, providing concrete analyses with cases and data on business opportunities. It will further attract global businesses to leverage Hong Kong's business platform and professional services."Prof Ma also pointed out that under 'One Country, Two Systems', Hong Kong possesses unique advantages in connecting both Hong Kong and international markets, playing a vital role as a superconnector and super value-adder.He continued, "As an international investment and financial centre, Hong Kong can provide diverse financing channels and options for infrastructure projects in the mainland and other regions, contributing to the high-quality development of the Belt and Road Initiative." The 10th Belt and Road Summit will be held from 10 to 11 September, promoting multilateral cooperation.The HKTDC will continue to align with HKSAR policies, actively promoting Hong Kong's business advantages, facilitating international trade and business activities and providing comprehensive support, especially for SMEs.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Sam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.org   About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 30, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK) recently announced via the Hong Kong Stock Exchange that it repurchased 17.65 million shares through on-market transactions on July 29, 2025, with a total consideration of HK$32.301 million. The repurchase price ranged from HK$1.80 to HK$1.86 per share. This marks another substantial buyback in the past month, reflecting management’s firm confidence in the company’s intrinsic value and long-term development.According to data, since July 2025, Shoucheng Holdings has cumulatively repurchased approximately 36.746 million shares, with a total expenditure of HK$66.7313 million. In addition to the July 29 buyback, the company executed another significant repurchase on July 10, acquiring 19.05 million shares for HK$34.3464 million at a price range of HK$1.79–1.80.Share repurchases are among the strongest signals a listed company can send to the market. In the face of short-term market volatility, Shoucheng has chosen to act decisively, reaffirming its responsibility to shareholders and its long-term value commitment. Management has conveyed a clear message: the company is committed to defending its fundamentals and investor confidence with concrete capital actions.Management stated: “We remain firmly optimistic about the long-term value of Shoucheng Holdings and are confident in our strategic direction, operational foundation, and future growth. This round of repurchases reflects our duty as a listed company to our shareholders, the market, and the company itself. We will continue to step forward at key moments to stabilize expectations and fulfill our long-term commitments to investors.”As a leading smart infrastructure asset operator in China, Shoucheng has deeply invested in core business sectors including equity investment, REITs, industrial real estate, and smart parking. It has built a strong asset cycle and cash flow system. In emerging sectors such as robotics and new infrastructure, the company continues to unlock growth potential and industrial synergy.Industry observers note that in today’s undervalued Hong Kong market, Shoucheng’s large-scale repurchase sends a clear signal: the company is prepared to reward long-term investors through steady performance, solid fundamentals, and disciplined capital management—true to its role as a creator of long-term value.With strong fundamentals and buybacks reinforcing support, Shoucheng Holdings’ future market performance is worth watching.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Wintermar’s Operating Profit jumped 55.8%YOY to US$8.9million for 1H2025,  derived from 17% growth in Owned Vessel Revenue in 1H2025 and higher gross margins from better fleet mix and higher charter rates.Owned Vessel revenues were higher in 1H2025 compared to 1H2024 despite lower utilization due to better yielding vessels in operation in 1H2025.         Owned Vessel DivisionAlthough the number of vessels has not changed, fleet composition has improved with 2 additional PSVs in operation in 1H2025 as well as 3 newly delivered HLBs which 2 units commenced work in April 2025 and 1 unit in July 2025.  With 4 additional units of higher yielding vessels in operation compared to last year, gross margins from the Owned Vessels Division expanded from 29.6% in 1H2024 to 39.1% in 1H2025.  This resulted in a 54.4%YOY jump in Gross Profit growth for the Owned Vessel Division to US$12.4million, despite a fall in utilization from 63.7% in FY2024 to 57.9% in 1H2025.Despite a slower first half of the year which caused a dip in utilization, the Company reaped the benefit of improving average charter rates from a higher number of operational vessels at the higher value segment of the fleet.  Owned Vessel Expenses increased by 22%QOQ from 1Q2025 to 2Q2025 due to an increase of fleet as well as Operational costs.                                       Chartering Division and Other ServicesChartering revenues experienced a sharp decline, as several vessels ended a contract which has not been renewed. Gross Profit from Chartering fell from US$0.7million in 1H2024 to US$0.2million in 1H2025.Gross Profit from Other Services fell to US$1.4million (-11.5%YOY) in1H2025 in line with the lower vessel utilization for the period compared to last year.                      Direct Expenses and Gross ProfitTotal Owned Vessel Direct Expenses rose only slightly by 1.3%YOY to US$19.4million for 1H2025. The largest increase came from Fuel Bunker costs which rose to US$1.4million (+46.1%YOY) due to the mobilization of vessels to overseas contracts. All other costs were lower except for Fleet Maintenance which rose 2.2%YOY to US$4.1million in 1H2025.On a quarterly basis, there were higher operational and maintenance costs in 2Q2025 compared to 1Q2025 due to the preparation and mobilization of a mid-tier vessel for a long-term contract in the Middle East.                     Indirect Expenses and Operating ProfitTotal Indirect Expense rose by 11.0%YOY to US$5.1million in 1H2025. The largest increase came from salary and employee benefits which rose by 10.0%YOY and 16.9%YOY to US$3.8million and US$0.2million respectively. With the improvement in business conditions and a wider geographic spread of operations, there was an increase in the number of employees in 2025 compared to last year. Telecommunications and marketing costs also rose with more international projects and higher costs of bid bond fees in the tender process.Due to good cost control, Operating Profit for 1H2025 jumped by 55.8% to US$8.9million from US$5.7million in the previous year.                 Other Income, Expenses and Net Attributable ProfitAs the Company refinanced the newly acquired vessels from the past year, interest expenses rose to US$1million for 1H2025, while interest income also doubled to US$0.3million due to strong operational cash flow.There was a turnaround in Equity in net earnings of Associates from a loss of US$0.4million in 1Q2025 to a profit of US$0.7million in 2Q2025. This resulted in a gain of US$0.6million from Investment in Associates for 1H2025, slightly lower than US$0.8million in 1H2024.During 2Q2025, management successfully sold a smaller mid-tier vessel for a profit, resulting in a net gain on sale of fixed asset of US$1.7million. This is in line with the continued fleet renewal program where smaller mid-tier vessels which are lower yielding will continue to be sold off to concentrate the fleet on larger and higher yielding vessels. However, this cannot compare with the significant one-off gain of US$17.4million recorded in 1H2024 primarily from the sale of a platform supply vessel. Therefore, total Other Income was US$1.7million for 1H2025 as compared to US$17.4million in 1H2024 which included the one-off vessel sale.Net income before tax for 1H2025 totalled US$10.7million, compared to US$23.2million in 1H2024. This 53.8% decline does not reflect the underlying improvement in the core business as 1H2024 profit included the sizable one-off gain from the vessel sale. Non-Controlling Interest fell from US$6.4 million in 1H2024 which included some profit from the sale of vessel to US$2.7 million in 1H2025. The group’s EBITDA jumped by 25.8%YOY for 1H2025, reaching US$16.0 million compared to US$12.7million in 1H2024.Stripping out the impact of vessel sales, the underlying profit for 1H2025 was US$ 5.4million compared to US$4.9million in 1H2024 representing a growth of 10.1%YOY.Industry Outlook                   There are growing signs of a pivot from renewable energy back to hydrocarbons as the world faces a growing need for energy while renewable sources of fuel are still insufficient and less economical. The continuing uncertainty in the Middle East and ongoing wars in Ukraine and Gaza have put pressure on governments around the world to seek energy security. In addition, the increasing need for energy for the “Green Transition” and data centres has led to a resurgence of demand for oil and gas. These factors have led to projections for global investment in oil and gas being maintained above US$610 billion in the coming years, with a steadily growing share invested into offshore fields. In Indonesia, the government has continued to push for self-sufficiency in various sectors, with energy being one of the sectors benefitting from this plan.  There are at present four sizeable strategic national projects in Indonesian offshore fields which are currently in the early stage of exploration and where production is expected from 2026-2030. These projects will sustain demand for OSVs in Indonesia in the coming years.Business ProspectsThe Company’s focus on developing a strong presence in the dynamic positioning segment is bringing in benefits of a higher blended fleet charter rate which has led to higher gross margins.  The 3 units of newly built HLB which commenced work in April to July 2025 will underpin earnings in 2H2025, and there is a third reactivated PSV expected to be operational at the end of 3Q2025. The investment cycle for oil and gas is still expected to ramp up for the next few years, providing better fleet utilization which will lead to profit upside.The stronger cash flow arising from a low debt position has enabled the Company to continue investing into higher value vessels while selling lower yielding vessels.  The additional vessels coming into operation in 2025 will provide upside for 2026 earnings.                  Total contracts on hand as at end June 2025 has risen to US$70.9 million.About Wintermar Offshore Marine GroupWintermar Offshore Marine Group (WINS.JK), developed over nearly 50 years with a track record of quality that is both a source of pride and responsibility that we are dedicated to upholding, and sails a fleet of more than 48 Offshore Support Vessels ready for long term as well as spot charters. All vessels are operated by experienced Indonesian crew, tracked by satellite systems and monitored in real-time by shore-based Vessel Teams.Wintermar is the first shipping company in Indonesia to be certified with an Integrated Management System by Lloyd's Register Quality Assurance, and is currently certified with ISO 9001:2015 (Quality), ISO14001:2015 (Environment) and OHSAS 18001:2007 (Occupational Health and Safety). For more information, please visit www.wintermar.com.For further information, please contact:Ms. Pek Swan Layanto, CFAInvestor RelationsPT Wintermar Offshore Marine TbkTel (62-21) 530 5201 Ext 401Email: investor_relations@wintermar.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum-resistant security validations across both Web3 and traditional Web2 infrastructures. Embedded at the Sub-Zero layer within a Decentralized Trust Mesh, $NAORIS powers autonomous device-to-device security challenges that trigger token swaps per block, ensuring continuous, automated trust without human input. Each node earns influence and rewards based on its trust score, creating a dynamic consensus system rooted in behavior and reliability. Token holders can stake to secure the network and participate in governance, aligning incentives with long-term protocol resilience.The announcement comes just weeks after Naoris raised $3 million in a strategic funding round led by Mason Labs, with participation from Frekaz Group, Level One Robotics and Tradecraft Capital.The $NAORIS token is the core utility asset powering this infrastructure, enabling access to security services, governance and incentives for network participants. As the lifeblood of the Naoris Protocol, $NAORIS serves as the cyber-trust primitive that drives decentralized security infrastructure across blockchains, enterprises and IoT ecosystems.Operating at the Sub-Zero Layer, beneath L0 to L2 blockchains, Naoris Protocol provides the trust and security fabric for decentralized applications and existing internet infrastructure. It integrates directly with EVM-compatible blockchains without requiring hard forks and extends protection to blockchain transactions, physical infrastructure, including enterprise systems, cloud platforms, IoT devices, validators, bridges and decentralized exchanges. Naoris Protocol’s Post-Quantum technology is aligned with NIST, NATO and ETSI post-quantum standards – the US Government has mandated that all digital systems transition to post-quantum cryptographic standards by 2030, with legacy algorithms fully phased out by 2035.“At Naoris, we firmly believe that blockchains cannot retrofit their way to post-quantum security, they must be built into the infrastructure from the ground up,” said Naoris CEO and Founder David Carvalho. “Our TGE helps us move closer to delivering the next standard in cyber-resilient infrastructure,ensuring global systems remain secure in the post-quantum era.”Naoris’ architecture combines Post-Quantum Cryptography, Decentralized Proof-of-Security (dPoSec) consensus, and Swarm AI to secure blockchain transactions and web infrastructure against quantum computing risks. Key features include:Quantum-Secure Blockchain Transactions: Enhances EVM blockchains against quantum threats without network disruptions.Trusted Web3 Infrastructure: Immutable, real-time mesh network secures nodes, validators, bridges, and DEXs.Distributed Web2 Security: Converts all devices into validator nodes, forming a self-healing network without single points of failure.Since launching its testnet in January, Naoris Protocol has recorded significant growth, with over 100 million post-quantum transactions processed, over 3.3 million wallets onboarded, over 1M security nodes and over 475 million cyber threats mitigated as well as 31 active projects under development across sectors such as finance, telecom, energy, defense, and IoT.Alongside CEO and Founder David Carvalho, Naoris Protocol is guided by a leadership team with deep expertise across cybersecurity, defense, and blockchain verticals, bringing together a diverse range of global experience. The team includes David Holtzman, former CTO of IBM and a key architect of the DNS protocol; Ahmed Réda Chami, Ambassador of Morocco to the European Union and former CEO of Microsoft North Africa; Mick Mulvaney, former White House Chief of Staff; and Inge Kampenes, retired Major General and former Chief of the Norwegian Armed Forces Cyber Defence. Their combined backgrounds reflect the protocol’s focus on building secure, scalable infrastructure for both Web3 and traditional systems.To learn more about Naoris Protocol, users can visit https://www.naorisprotocol.com/ About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks.Media Contact: sharon@babslabs.io  Disclaimer: All product and company names herein may be trademarks of their registered owners.  The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Copyright 2025 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease.No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).Abidin Gülmüs, Chairman of GEN, stated:"We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease."About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's "powerhouse." It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GünesSr. Head of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comKees van der GraafSulfateq CEOinfo@sulfateqbv.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company's leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification and the Climate, Community and Biodiversity Standards (CCB) - CCB-Biodiversity Gold Level certification.In recent years, GTJAI has been continuously reducing its operational carbon footprint through systematic energy saving and emission reduction initiatives, which is the core support for the achievement of “carbon neutrality”, including vigorously implementing energy-saving renovation of office space, deepening digitalization and paperless transformation, and implementing stringent waste management (100% safe recycling of hazardous waste by 2024). Solid internal emission reduction efforts, combined with carbon offsetting through high-quality carbon credits, enabled the Company to achieve “carbon neutrality” at the operational level.Adhering to the core philosophy of “finance for the country, finance for the people, finance for the good”, GTJAI has always placed sustainable development at the core of its corporate strategy. The Company is committed to supporting the real economy through financial services while facilitating the green transformation of its corporate clients. In 2024, the Company successfully completed 90 sustainable finance projects covering green bonds, sustainable bonds and green sector IPOs with a total issuance volume of HK$179.8 billion, significantly broadening the financing pipeline for the green industry. Meanwhile, the private equity sector is actively engaged in the sustainability sector, with more than half of its investments focusing on ESG-related industries.Looking ahead, GTJAI will deepen the level of ESG governance, fully integrate ESG factors into its operations and management processes, further leverage its professional strengths and enhance the level of green financial services capabilities. Through innovative products and services, GTJAI will proactively contribute to the realization of the country's “dual carbon” goal and promote the high-quality development of the economy and society.About GTJAIGuotai Junan International (“GTJAI”, Stock Code: 1788.HK), a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH; 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.